Roquefort Therapeutics demonstrates initial safety in two antibody programmes
News release by Roquefort Therapeutics PLC
London, UK | January 26, 2023 03:00 AM Eastern Standard Time
Roquefort Therapeutics PLC (LSE:ROQ, OTCQB:ROQAF) CEO Ajan Reginald speaks to Proactive's Thomas Warner after announcing that the company's ROQ-A1 and ROQ-A2 Midkine (MDK) antibody programmes have successfully demonstrated safety in pre-clinical studies. Reginald says that he's now hoping to "move rapidly into efficacy testing".
Proactive UK Ltd
+44 20 7989 0813